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patients with poor physical health, any contribution
from impaired vision is difficult to distinguish from
that of comorbid disorders. Health utility measures
such as the standard gamble and time trade-off
techniques are also inappropriate.4 Elderly people
have problems understanding the hypothetical con-
cepts of the percentage of risk of death that they would
be prepared to accept to avoid chronic ill health or the
number of years of life they would be prepared to trade
for a perfect cure for their medical condition. Also such
questions would be difficult for elderly people to
answer given their shorter life expectancies.
Most visual functioning questionnaires assess the
impact of visual loss on daily living but do not measure
social or psychological functioning.4 Though some
questionnaires—such as the National Eye Institute
visual functioning questionnaire—do measure psycho-
logical aspects of visual impairment,6 they are
unresponsive to small differences in visual acuity. The
authors of the review recommend their own instru-
ment the MacDQoL,7 which measures the impact of
age related macular degeneration on quality of life and
can discriminate between mild and moderate disease.
The usefulness of this tool is difficult to assess, however,
as what constitutes mild or moderate age related
macular degeneration is not defined.
Vision is a complex neurosensory task mediated by
both eyes, so that wet macular degeneration in one eye
does not necessarily affect quality of life. The
commonly measured surrogate marker visual acuity
also correlates poorly with the severity of retinal
changes.8 9 Many people develop adaptive strategies
over time that cannot be captured in cross sectional
studies and are difficult to control for even in longitu-
dinal studies. Thus, the criticism that most existing
visual functioning questionnaires lack the sensitivity to
differentiate severity of disease would appear to be
unduly harsh, as appropriately designed large longitu-
dinal studies have not yet been undertaken.
Mitchell and Bradley state that despite the develop-
ment of promising new treatments,10 none has used an
effective measure of quality of life to evaluate benefit.
Treatments that are unpleasant, need repeated admin-
istration, and cause adverse effects are likely to reduce
quality of life even though they may improve visual
acuity. An ideal instrument for use in wet macular
degeneration will be responsive to changes in visual
function and quality of life as well as capture
satisfaction with treatment. Such an instrument is
needed now.
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Spirometry in chronic obstructive pulmonary
disease
Is available, yet underused in general practice
Chronic obstructive pulmonary disease affectsabout 1% of the total UK population1 and is amajor cause of disability and mortality
worldwide. Timely diagnosis and subsequent staging of
severity of disease both require spirometry, which in
theory can be performed by trained general practition-
ers (GPs) and their practice staff.2 3 However, numerous
barriers impede the implementation of spirometry in
primary care.
Several guidelines exist for the management of
patients with chronic obstructive pulmonary disease,
including those from the UK National Institute for
Health and Clinical excellence (NICE)4 and the Global
Initiative for Chronic Obstructive Lung Disease
(GOLD; www.goldcopd.com). All guidelines stress the
central role of spirometry in diagnosing and managing
the disease in primary care, but this does not guarantee
that GPs will use this technique consistently in the care
of patients with respiratory symptoms.5
Several models to provide spirometry test results
exist, depending on local circumstances; these include
regional primary care diagnostic services and hospital
based lung function laboratories with open access for
primary care patients.6 However, the most practical and
timely solution is for GPs to have their own spirometer
in the practice.7 In the United Kingdom about 80% of
general practices own a spirometer,8 but these
instruments are still scarce in large parts of the world,
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even though prices have dropped considerably in the
past few years. Trained practice staff who have the skills
and time to fit and maintain spirometry of sufficient
quality into the daily practice routine9 may also be in
short supply.10 In addition to the practical issues, GPs’
lack of confidence in their ability to interpret the test
results is a crucial barrier—often neglected in the
guidelines to effective implementation of spirometry.8
Many GPs view spirometry as a complex diagnostic
tool, like electrocardiography. This fact was clearly
illustrated in a recent UK study that reported low levels
of self confidence in interpreting spirometric tests in
160 general practices where GPs and nurses had been
trained for half a day—only a third of these profession-
als trusted their own interpretative skills.8 Confidence
about how to proceed once the test results are available
is a crucial part of building GPs’ confidence in their
capacity to diagnose and manage the disease.
Ideally once GPs have had initial spirometry train-
ing they should receive continuous advice and support.
This could be done in various ways—by another GP
with a special interest in respiratory diseases in the
same practice or in another practice nearby; by means
of a computerised clinical decision support system
(SpidaXpert software; www.spirxpert.com); or by
consultation or feedback from a chest physician.
Although intuitively a promising idea, empirical
studies on the effects of ongoing expert support on the
interpretative capacity and self confidence of GPs are
lacking.
So what needs to happen next? For guidelines on
chronic obstructive pulmonary disease to be imple-
mented, concrete working agreements between GPs
and chest physicians need to be developed. Chest phy-
sicians can act as coaches for their local primary care
colleagues in two ways—through patient oriented sup-
port (specific feedback for specific patients) or through
practice oriented support (as teachers in postgraduate
training programmes). This will be beneficial for both
parties, as referrals will be more structured and based
on agreed criteria, GPs who have performed
spirometry will have better insight into the patient’s
lung function, and chest physicians will benefit from
having the results at the initial consultation.11 More
broadly, coordinated efforts by health policy makers
and the medical profession will be needed to provide
the right equipment, training for staff who use it, and
continuing quality assurance and support for test
interpretation. The burden of chronic obstructive pul-
monary disease is sufficiently large to warrant such an
approach.
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A European alcohol strategy
Will the opportunity be missed?
This month the European Commission mustdecide whether to adopt a strategy to deal withthe adverse health consequences of alcohol.
The strategy has been awaited eagerly by Europe’s
public health community since it was first mooted five
years ago, but it could fall at the last hurdle. It may be
the victim of a carefully planned attack by representa-
tives of the alcohol industry, using tactics associated
with tobacco manufacturers.
Alcohol related disease accounts for almost 8% of
the overall burden of disease in Europe.1 One factor
contributing to the current level of consumption is the
single European market, testified to by the existence of
vast retail outlets around Calais that thousands of Brit-
ish travellers visit each week. Yet the single market has
implications that go far beyond this type of cross
border trade. Countries such as Sweden and Finland
had longstanding stringent controls on alcohol sales
that restricted access to low cost alcohol. After they
joined the European Union in 1995 they had to
dismantle important parts of their policies,2 and over
the next decade death rates from cirrhosis in Finland
rose by 50%.3 The industry has also used the single
This article was posted on bmj.com on 17 October 2006: http://bmj.com/
cgi/doi/10.1136/bmj.39003.629606.BE
Editorials
BMJ 2006;333:871–2
871BMJ VOLUME 333 28 OCTOBER 2006 bmj.com
